Sartorius Stedim Biotech DIM.PA
Sartorius Stedim Biotech is a leading provider of equipment, consumables, and solutions for biopharmaceutical manufacturing, with a business model based on selling single-use products and services to the biotech and pharmaceutical industry. Sartorius Stedim Biotech shows solid financial health (score 6.0) and 37.1% profit growth, but its valuation is extremely demanding (P/E 71.85), making it vulnerable to a rising rate environment in Europe.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Sartorius Stedim Biotech is a leading provider of equipment, consumables, and solutions for biopharmaceutical manufacturing, with a business model based on selling single-use products and services to the biotech and pharmaceutical industry. Sartorius Stedim Biotech shows solid financial health (score 6.0) and 37.1% profit growth, but its valuation is extremely demanding (P/E 71.85), making it vulnerable to a rising rate environment in Europe.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.0 |
| Quality / Moat | 4.6 |
| Valuation | 2.0 |
| Growth | 6.8 |
| Dividend | 4.2 |
| Momentum | 4.4 |
| Risk & Context | 4.3 |
OVERALL SCORE: 4.5/10
Context and risks
The company has significant exposure to tariffs in its global operations, as mentioned in its own Q2 2026 earnings call. The current tariff regime is fragile and litigious, adding regulatory uncertainty to the business model.
News considered in the analysis
- Sartorius Stedim Biotech SA (SDMHF) Q2 2026 Earnings Call Highlights: Strong Growth Amid Tariff ... — Resultados del Q2 con crecimiento sólido, pero la mención a aranceles sugiere un viento en contra que podría estar parcialmente descontado.
- European Stocks Possibly Trading Below Estimated Value May 2026 — Listículo genérico sin información específica sobre la empresa.
- Sartorius Stedim Biotech SA (SDMHF) Q4 2025 Earnings Call Highlights: Strong Profit Growth and ... — Resultados del Q4 2025 ya conocidos y reflejados en el precio actual.
- Discover 3 European Stocks Believed To Be Trading Below Intrinsic Value — Artículo promocional sin análisis fundamental nuevo.
Verdict: Hold; the quality of the business and growth do not justify the current multiple in a context of rising rates.
Main risk: The valuation of 71.85 times earnings is the biggest risk: any disappointment in future growth or further ECB tightening could trigger a significant correction.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →